- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | MICROBA LIFE SCIENCES LIMITED: Change in substantial holding | - | ASX | ||
| 26.08. | Microba Life Sciences Reports Revenue Growth, Reduced Losses in Preliminary Final Report | 1 | Finance News Network | ||
| 26.08. | MICROBA LIFE SCIENCES LIMITED: 2025 Annual Report & Appendix 4E | - | ASX | ||
| 26.08. | MICROBA LIFE SCIENCES LIMITED: 2025 Appendix 4G | - | ASX | ||
| 26.08. | MICROBA LIFE SCIENCES LIMITED: 2025 Corporate Governance Statement | - | ASX | ||
| 19.08. | MICROBA LIFE SCIENCES LIMITED: Notice of change of Interests of substantial holder from SHL | 1 | ASX | ||
| MICROBA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 19.08. | MICROBA LIFE SCIENCES LIMITED: Change in substantial holding | 2 | ASX | ||
| 15.08. | MICROBA LIFE SCIENCES LIMITED: Corrected Change of Director's Interest Notice | 1 | ASX | ||
| 15.08. | MICROBA LIFE SCIENCES LIMITED: Change of Director's Interest Notice - Pasquale Rombola | - | ASX | ||
| 15.08. | MICROBA LIFE SCIENCES LIMITED: Change of Director's Interest Notice - Prof Ian Frazer | 1 | ASX | ||
| 13.08. | MICROBA LIFE SCIENCES LIMITED: Cleansing Notice | - | ASX | ||
| 13.08. | MICROBA LIFE SCIENCES LIMITED: Notification regarding unquoted securities - MAP | - | ASX | ||
| 13.08. | MICROBA LIFE SCIENCES LIMITED: Notification regarding unquoted securities - MAP | - | ASX | ||
| 13.08. | MICROBA LIFE SCIENCES LIMITED: Notification regarding unquoted securities - MAP | 1 | ASX | ||
| 13.08. | MICROBA LIFE SCIENCES LIMITED: Application for quotation of securities - MAP | - | ASX | ||
| 13.08. | MICROBA LIFE SCIENCES LIMITED: Application for quotation of securities - MAP | - | ASX | ||
| 11.08. | MICROBA LIFE SCIENCES LIMITED: Successful completion of $2.0m Share Purchase Plan | 1 | ASX | ||
| 08.08. | MICROBA LIFE SCIENCES LIMITED: Results of General Meeting | - | ASX | ||
| 22.07. | Microba Q4 FY25 slides reveal 88% growth in core tests amid strategic pivot | 1 | Investing.com | ||
| 21.07. | MICROBA LIFE SCIENCES LIMITED: Q4 FY25 Quarterly Investor Presentation & Webinar | - | ASX |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MINERALYS THERAPEUTICS | 28,860 | 0,00 % | Mineralys Therapeutics prices upsized $250M stock offering | ||
| AVIDITY BIOSCIENCES | 47,230 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 40,690 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update | Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,200 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ARCELLX | 69,75 | 0,00 % | Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial | ||
| TARSUS PHARMACEUTICALS | 58,59 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,840 | 0,00 % | H.C. Wainwright hebt Kursziel für Summit Therapeutics auf 50 US-Dollar an | ||
| TREVI THERAPEUTICS | 7,270 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| NUVALENT | 76,90 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 44,940 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Participate in Upcoming Fireside Chat | ||
| UPSTREAM BIO | 20,260 | 0,00 % | Upstream Bio, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 4,660 | 0,00 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
| CG ONCOLOGY | 27,460 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates | - Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - ... ► Artikel lesen | |
| BEAM THERAPEUTICS | 16,310 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| DYNE THERAPEUTICS | 13,500 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen |
Das Unternehmen MICROBA LIFE SCIENCES LIMITED kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,002 (+3,37 %) liegt der Kurs bei 0,046 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MICROBA LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.